Literature DB >> 11034583

Effects of a serotonin 5-HT(4) receptor antagonist SB-207266 on gastrointestinal motor and sensory function in humans.

A E Bharucha1, M Camilleri, S Haydock, I Ferber, D Burton, S Cooper, D Tompson, K Fitzpatrick, R Higgins, A R Zinsmeister.   

Abstract

BACKGROUND: Serotonin 5-HT(4) receptors are located on enteric cholinergic neurones and may regulate peristalsis. 5-HT(4) receptors on primary afferent neurones have been postulated to modulate visceral sensation. While 5-HT(4) agonists are used as prokinetic agents, the physiological role of 5-HT(4) receptors in the human gut is unknown. AIMS: Our aim was to characterise the role of 5-HT(4) receptors in regulating gastrointestinal motor and sensory function in healthy subjects under baseline and stimulated conditions with a 5-HT(4) receptor antagonist.
METHODS: Part A compared the effects of placebo to four doses of a 5-HT(4) receptor antagonist (SB-207266) on the cisapride mediated increase in plasma aldosterone (a 5-HT(4) mediated response) and orocaecal transit in 18 subjects. In part B, 52 healthy subjects received placebo, or 0.05, 0.5, or 5 mg of SB-207266 for 10-12 days; gastric, small bowel, and colonic transit were measured by scintigraphy on days 7-9, and fasting and postprandial colonic motor function, compliance, and sensation during distensions were assessed on day 12.
RESULTS: Part A: 0.5, 5, and 20 mg doses of SB-207266 had significant and quantitatively similar effects, antagonising the cisapride mediated increase in plasma aldosterone and acceleration of orocaecal transit. Part B: SB-207266 tended to delay colonic transit (geometric centre of isotope at 24 (p=0.06) and 48 hours (p=0.08)), but did not have dose related effects on transit, fasting or postprandial colonic motor activity, compliance, or sensation.
CONCLUSION: 5-HT(4) receptors are involved in the regulation of cisapride stimulated orocaecal transit; SB 207266 tends to modulate colonic transit but not sensory functions or compliance in healthy human subjects.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11034583      PMCID: PMC1728108          DOI: 10.1136/gut.47.5.667

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  33 in total

1.  Assessment of functional gastrointestinal disease: the bowel disease questionnaire.

Authors:  N J Talley; S F Phillips; C M Wiltgen; A R Zinsmeister; L J Melton
Journal:  Mayo Clin Proc       Date:  1990-11       Impact factor: 7.616

2.  Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans.

Authors:  E P Bouras; M Camilleri; D D Burton; S McKinzie
Journal:  Gut       Date:  1999-05       Impact factor: 23.059

3.  5-HT4 receptor antagonism in irritable bowel syndrome: effect of SB-207266-A on rectal sensitivity and small bowel transit.

Authors:  L A Houghton; N A Jackson; P J Whorwell; S M Cooper
Journal:  Aliment Pharmacol Ther       Date:  1999-11       Impact factor: 8.171

4.  Investigation of the role of 5-HT3 and 5-HT4 receptors in ascending and descending reflexes to the circular muscle of guinea-pig small intestine.

Authors:  S Y Yuan; J C Bornstein; J B Furness
Journal:  Br J Pharmacol       Date:  1994-08       Impact factor: 8.739

5.  Screening for surgically correctable hypertension caused by primary aldosteronism.

Authors:  R M Carey
Journal:  Arch Intern Med       Date:  1981-11

6.  Coloanal motor coordination in association with high-amplitude colonic contractions after pharmacological stimulation.

Authors:  A Malcolm; M Camilleri
Journal:  Am J Gastroenterol       Date:  2000-03       Impact factor: 10.864

7.  Serotonergic mediation of postprandial colonic tonic and phasic responses in humans.

Authors:  M R von der Ohe; R B Hanson; M Camilleri
Journal:  Gut       Date:  1994-04       Impact factor: 23.059

8.  Benzamide derivatives provide evidence for the involvement of a 5-HT4 receptor type in the mechanism of action of serotonin in frog adrenocortical cells.

Authors:  S Idres; C Delarue; H Lefebvre; H Vaudry
Journal:  Brain Res Mol Brain Res       Date:  1991-06

9.  The hospital anxiety and depression scale.

Authors:  A S Zigmond; R P Snaith
Journal:  Acta Psychiatr Scand       Date:  1983-06       Impact factor: 6.392

10.  Human gastric emptying and colonic filling of solids characterized by a new method.

Authors:  M Camilleri; L J Colemont; S F Phillips; M L Brown; G M Thomforde; N Chapman; A R Zinsmeister
Journal:  Am J Physiol       Date:  1989-08
View more
  31 in total

Review 1.  Testing the sensitivity hypothesis in practice: tools and methods, assumptions and pitfalls.

Authors:  M Camilleri
Journal:  Gut       Date:  2002-07       Impact factor: 23.059

Review 2.  Serotonergic modulating drugs for functional gastrointestinal diseases.

Authors:  Robin Spiller
Journal:  Br J Clin Pharmacol       Date:  2002-07       Impact factor: 4.335

Review 3.  Pharmacology of serotonin: what a clinician should know.

Authors:  F De Ponti
Journal:  Gut       Date:  2004-10       Impact factor: 23.059

Review 4.  Visceral hypersensitivity and electromechanical dysfunction as therapeutic targets in pediatric functional dyspepsia.

Authors:  John M Rosen; Jose T Cocjin; Jennifer V Schurman; Jennifer M Colombo; Craig A Friesen
Journal:  World J Gastrointest Pharmacol Ther       Date:  2014-08-06

5.  Short-Term Effects of Relamorelin on Descending Colon Motility in Chronic Constipation: A Randomized, Controlled Trial.

Authors:  Andres Acosta; Michael Camilleri; Irene Busciglio; Amy Boldingh; Alfred D Nelson; Duane Burton
Journal:  Dig Dis Sci       Date:  2015-10-14       Impact factor: 3.199

6.  Relationship between symptoms and disordered continence mechanisms in women with idiopathic faecal incontinence.

Authors:  A E Bharucha; J G Fletcher; C M Harper; D Hough; J R Daube; C Stevens; B Seide; S J Riederer; A R Zinsmeister
Journal:  Gut       Date:  2005-04       Impact factor: 23.059

7.  Tegaserod inhibits noxious rectal distention induced responses and limbic system c-Fos expression in rats with visceral hypersensitivity.

Authors:  Hong-Mei Jiao; Peng-Yan Xie
Journal:  World J Gastroenterol       Date:  2004-10-01       Impact factor: 5.742

Review 8.  Role of serotonin in the pathophysiology of the irritable bowel syndrome.

Authors:  Michael D Crowell
Journal:  Br J Pharmacol       Date:  2004-04       Impact factor: 8.739

9.  Analysis of rectal dynamic and static compliances in patients with irritable bowel syndrome.

Authors:  Jung Ho Park; Yoo Hum Baek; Dong I L Park; Hong Joo Kim; Yong Kyun Cho; Chong I L Sohn; Woo Kyu Jeon; Byung Ik Kim; Poong-Lyul Rhee
Journal:  Int J Colorectal Dis       Date:  2008-03-21       Impact factor: 2.571

10.  L-Lysine acts like a partial serotonin receptor 4 antagonist and inhibits serotonin-mediated intestinal pathologies and anxiety in rats.

Authors:  Miro Smriga; Kunio Torii
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.